NEW YORK (GenomeWeb) – Molecular diagnostics firm Signal Genetics and the University of Texas MD Anderson Cancer Center have announced an agreement to evaluate the clinical utility of Signal's MyPRS test for symptomatic multiple myeloma risk.

The microarray-based MyPRS test identifies patients with asymptomatic monoclonal gammopathies, including smoldering multiple myeloma and MGUS, with a high or low risk for rapid progression to symptomatic multiple myeloma.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.